Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price traded up 1.8% during trading on Monday . The stock traded as high as $7.22 and last traded at $7.16, with a volume of 63,753 shares trading hands. The stock had previously closed at $7.03.

Several equities analysts have recently commented on the company. Jefferies Group lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 price target on the stock. in a research note on Wednesday, June 1st. Wedbush reiterated an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, June 10th. Leerink Swann reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Sunday, June 12th. Zacks Investment Research lowered Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Finally, Raymond James Financial Inc. initiated coverage on Karyopharm Therapeutics in a research note on Friday, May 27th. They issued an “outperform” rating and a $13.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $19.50.

The firm’s market capitalization is $256.39 million. The firm has a 50 day moving average of $7.64 and a 200 day moving average of $7.81.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Monday, May 9th. The company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.74) by $0.01. On average, analysts forecast that Karyopharm Therapeutics Inc. will post ($3.09) EPS for the current year.

In other news, major shareholder Ltd Chione sold 18,824 shares of the company’s stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $8.03, for a total value of $151,156.72. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC raised its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned approximately 0.25% of Karyopharm Therapeutics worth $1,167,000 as of its most recent SEC filing.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.